Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20053013 | 0.84 | — | — | |
| SCHEMBL20052932 | 0.80 | OPRM1 (0.32) | — | |
| SCHEMBL20052995 | 0.79 | POLL (0.37) | — | |
| SCHEMBL21850006 | 0.76 | SLC6A2 (0.32) | — | |
| SCHEMBL27927404 | 0.68 | HTR2A (0.39) | — | |
| SCHEMBL17710161 | 0.67 | KDM4E (0.44) | — | |
| SCHEMBL8358228 | 0.66 | CTSB (0.49) | CTSBGABRA1GABRB2HTT | |
| SCHEMBL20052967 | 0.66 | HTR1A (0.37) | — | |
| SCHEMBL24970171 | 0.66 | MEN1 (0.34) | — | |
| SCHEMBL28283505 | 0.65 | CTSB (0.47) | CTSBGABRA1GABRB2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472374-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190016732-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2019-01-17 | — | — | US | disclosed |
| US-9944655-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2018-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472374-B2 | ACC inhibitors and uses thereof | ACACA, ACACB, ACAT2 | CTSB 1534/4885PIM1 1863/4885GABRA1 2887/4885 |
| US-20190016732-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | CTSB 1534/4885PIM1 1863/4885GABRA1 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.